AEZS News 1.32 08/21/2014 04:28:18 Aeterna Zentaris (AEZS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris (AEZS) 1.32 $AEZS

4 Stocks Under $10 to Trade Now
at The Street - Fri Aug 15, 5:00AM CDT
Stocks making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst.

Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results
PR Newswire - Thu Aug 07, 3:30PM CDT
All amounts are in US dollars

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston
CNW Group - Wed Aug 06, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Canaccord Genuity 34th Annual Global Growth Conference on Wednesday, August 13, 2014, at 1pm (Eastern), in the Melbourne Room of the Intercontinental Hotel in Boston.

Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
PR Newswire - Tue Aug 05, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced a strategic co-promotion services agreement with ASCEND Therapeutics® US, LLC, ("ASCEND" . Under the terms of the agreement, expected to start in the fourth quarter of 2014, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel® a non-patch transdermal U.S. Food & Drug Administration ("FDA" approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency ("AGHD" , for which a New Drug Application ("NDA" is currently under review by the FDA, with a Prescription Drug User Fee Act ("PDUFA" date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.

Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014
CNW Group - Thu Jul 31, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its second quarter 2014 financial and operating results after market close on Thursday, August 7, 2014. The Company will host a conference call to discuss these results on Friday, August 8, 2014, at 8:30 a.m. eastern time.

Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:

Traders Get Bullish on Shares of AEterna Zentaris, Shares Up 6.6% (AEZS)
Comtex SmarTrend(R) - Wed Jul 02, 10:09AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $1.29 on 7.0x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 386,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.

Chronic Urticaria Or Hives - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nwxvjx/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Merck & Co., Inc. - Biofrontera AG - AEterna Zentaris Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/nw..._urticaria

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
CNW Group - Wed Jun 11, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, June 18, 2014, at 11:30 am (Eastern), in Room A-B, 4(th) floor of the Toronto Board of Trade in Toronto, Canada.

Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company
CNW Group - Tue Jun 10, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced the roll-out of a global resources optimization program as the Company pursues its strategy of transitioning into a commercially operating specialty biopharmaceutical company. Initiated earlier this year, the program's goal is to streamline R&D activities and increase commercial operations and flexibility. With the implementation of the global resources optimization program, the Company expects to have approximately 65 employees by year-end, as compared to 90 employees at the beginning of 2014. Due to the nature of certain proceedings, the Company intends to provide an estimate of the anticipated global restructuring charges and future cost savings as and when the financial and accounting implications of the global resources optimization program become better defined.

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
CNW Group - Tue Apr 01, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs
PR Newswire - Fri Mar 28, 4:23PM CDT
All amounts are in US dollars

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
PR Newswire - Thu Mar 20, 3:30PM CDT
All amounts are in US dollars
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 46

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 136

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 123

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading

Top 5 Most Recently Viewed Articles

Wicked Cutz, Cinnabon Team Up for Bacon Jerky Debut

Updated Category News Views 13

Ever thought you'd see the day when your protein snack could taste like a cinnamon roll? Well, folks, that day has arrived. Wicked Cutz, a force in the meat snack industry, and Cinnabon, the undisputed champs of cinnamon rolls, have rolled out a product that's bound to raise some eyebrows: bacon jerky with a sweet pastry twist. Why Bacon Jerky? You might be wondering, why...

Continue Reading
10 High-Yielding Small-Cap Stocks Under $15 in 2024

Updated Category Stocks Views 542

In the ever-evolving landscape of the stock market, small-cap stocks can be a gold mine for investors seeking high yields without breaking the bank. As we navigate through 2024, let's delve into a curated list of 10 small-cap stocks trading under $15 that offer attractive dividend yields. But remember, high yields can be as enticing as they are perilous, so tread with...

Continue Reading
Frazier Life Sciences Secures Over $630M for Growth Initiatives

Updated Category News Views 239

Frazier Life Sciences (FLS) raised over $630 million back in 2024, which got everyone buzzing on the trading floor. This wasn't just pocket change; it came from an oversubscribed fundraise that saw new and existing investors jumping on board like it was Black Friday. Talk about a cash infusion! The Public Fund has amassed around $1.7 billion since its launch three years...

Continue Reading
1847 Holdings LLC Achieves Milestone with $11.1M Offering

Updated Category News Views 112

1847 Holdings LLC Successfully Completes Public Offering 1847 Holdings LLC (NYSE American: EFSH), a company dedicated to investing in high-potential middle-market businesses, recently announced an exciting achievement. The firm has successfully closed its public offering, resulting in gross proceeds of $11.1 million. This accomplishment reflects the company's continued...

Continue Reading
Live Nation Entertainment's Stock Analysis Amid Sell-Off

Updated Category News Views 238

Understanding Live Nation Entertainment's Recent Stock Movements The trading landscape for Live Nation Entertainment, Inc. (LYV) has seen quieter activity following a significant sell-off of 6.5%. Investors and market analysts are closely observing whether this stock will continue its downward trajectory. Technical Analysis: Support and Resistance Levels Identifying Key...

Continue Reading